Alterations in plasma L-arginine and methylarginines in heart failure and after heart transplantation

Abstract Objective. Endothelial function, including the nitric oxide (NO)-pathway, has previously been extensively investigated in heart failure (HF). In contrast, studies are lacking on the NO pathway after heart transplantation (HT). We therefore investigated substances in the NO pathway prior to and after HT in relation to hemodynamic parameters. Design. 12 patients (median age 50.0 yrs, 2 females), heart transplanted between June 2012 and February 2014, evaluated at our hemodynamic lab, at rest, prior to HT, as well as four weeks and six months after HT were included. All patients had normal left ventricular function post-operatively and none had post-operative pulmonary hypertension or acute cellular rejection requiring therapy at the evaluations. Plasma concentrations of ADMA, SDMA, L-Arginine, L-Ornithine and L-Citrulline were analyzed at each evaluation. Results. In comparison to controls, the plasma L-Arginine concentration was low and ADMA high in HF patients, resulting in low L-Arginine/ADMA-ratio pre-HT. Already four weeks after HT L-Arginine was normalized whereas ADMA remained high. Consequently the L-Arginine/ADMA-ratio improved, but did not normalize. The biomarkers remained unchanged at the six-month evaluation and the L-Arginine/ADMA-ratio correlated inversely to pulmonary vascular resistance (PVR) six months post-HT. Conclusions. Plasma L-Arginine concentrations normalize after HT. However, as ADMA is unchanged, the L-Arginine/ADMA-ratio remained low and correlated inversely to PVR. Together these findings suggest that (i) the L-Arginine/ADMA-ratio may be an indicator of pulmonary vascular tone after HT, and that (ii) NO-dependent endothelial function is partly restored after HT. Considering the good postoperative outcome, the biomarker levels may be considered “normal” after HT.

[1]  G. Rådegran,et al.  Plasma l-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction , 2017, Heart and Vessels.

[2]  G. Rådegran,et al.  Impact of postoperative pulmonary hypertension on outcome after heart transplantation , 2017, Scandinavian cardiovascular journal : SCJ.

[3]  R. Wachter,et al.  Left ventricular heart failure and pulmonary hypertension , 2015, European heart journal.

[4]  Sanjiv J. Shah,et al.  Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. , 2015, JAMA.

[5]  G. Wikström,et al.  Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension. , 2015, Vascular pharmacology.

[6]  G. Rådegran,et al.  Hemodynamic Characteristics Including Pulmonary Hypertension at Rest and During Exercise Before and After Heart Transplantation , 2015, Journal of the American Heart Association.

[7]  C. Jung,et al.  Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? , 2013, Cardiovascular research.

[8]  S. Hazen,et al.  Diminished global arginine bioavailability as a metabolic defect in chronic systolic heart failure. , 2013, Journal of cardiac failure.

[9]  H. Figulla,et al.  Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion. , 2013, Clinical hemorheology and microcirculation.

[10]  N. Frey,et al.  The L-Arginine-asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy. , 2012, Journal of cardiac failure.

[11]  Shing‐Jong Lin,et al.  Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure. , 2012, Atherosclerosis.

[12]  A. Melidonis,et al.  Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure , 2012, Heart.

[13]  James D. Thomas,et al.  Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. , 2012, Journal of the American College of Cardiology.

[14]  V. Roger,et al.  Pulmonary pressures and death in heart failure: a community study. , 2012, Journal of the American College of Cardiology.

[15]  H. Arnesen,et al.  The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training. , 2011, Journal of cardiac failure.

[16]  W. Paulus,et al.  The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature , 2010, European journal of heart failure.

[17]  E. Benjamin,et al.  Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community , 2009, Circulation.

[18]  H. Valantine,et al.  Asymmetric Dimethylarginine and Cardiac Allograft Vasculopathy Progression: Modulation by Sirolimus , 2008, Transplantation.

[19]  Maristela L Onozato,et al.  Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. , 2007, American journal of physiology. Heart and circulatory physiology.

[20]  W. Durante,et al.  ARGINASE: A CRITICAL REGULATOR OF NITRIC OXIDE SYNTHESIS AND VASCULAR FUNCTION , 2007, Clinical and experimental pharmacology & physiology.

[21]  D. Kass,et al.  L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. , 2006, JAMA.

[22]  Silviu Itescu,et al.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  R. Böger Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. , 2004, The Journal of nutrition.

[24]  J. Kjekshus,et al.  Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension , 2002, Transplantation.

[25]  Shing‐Jong Lin,et al.  Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. , 2002, The American journal of cardiology.

[26]  A. Selwyn,et al.  The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. , 1998, The American journal of cardiology.

[27]  T. Imaizumi,et al.  Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. , 1998, Life sciences.

[28]  T. Rector,et al.  Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. , 1996, Circulation.

[29]  J. Cooke,et al.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.

[30]  S. Moncada,et al.  Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.